Characteristics of Subjects with Very Low Serum Low-Density Lipoprotein Cholesterol and the Risk for Intracerebral Hemorrhage |
Lee, Jae-Geun
(Department of Internal Medicine, Jeju National University School of Medicine)
Koh, Sung-Joo (Department of Internal Medicine, Jeju National University School of Medicine) Yoo, So-Yeon (Department of Internal Medicine, Jeju National University School of Medicine) Yu, Jung-Re (Department of Internal Medicine, Jeju National University School of Medicine) Lee, Sang-Ah (Department of Internal Medicine, Jeju National University School of Medicine) Koh, Gwan-Pyo (Department of Internal Medicine, Jeju National University School of Medicine) Lee, Dae-Ho (Department of Internal Medicine, Jeju National University School of Medicine) |
1 | Cziraky MJ, Watson KE, Talbert RL. Targeting low HDLcholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008;14(8 Suppl):S3-S28. |
2 | Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-822. DOI ScienceOn |
3 | O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-2146. DOI ScienceOn |
4 | Stemmermann GN, Chyou PH, Kagan A, Nomura AM, Yano K. Serum cholesterol and mortality among Japanese-American men: the Honolulu (Hawaii) Heart Program. Arch Intern Med 1991;151:969-972. DOI ScienceOn |
5 | Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men. JAMA 1995;273:1926-1932. DOI ScienceOn |
6 | Frank JW, Reed DM, Grove JS, Benfante R. Will lowering population levels of serum cholesterol affect total mortality? Expectations from the Honolulu Heart Program. J Clin Epidemiol 1992;45:333-346. DOI ScienceOn |
7 | Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial: multiple risk factor intervention trial research group. Arch Intern Med 1992;152:1490-1500. DOI ScienceOn |
8 | Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 2009;119:2136-2145. DOI ScienceOn |
9 | Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 2005;96(4A):53E-59E. |
10 | LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. DOI ScienceOn |
11 | Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008;102:1312-1317. DOI ScienceOn |
12 | Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278. DOI ScienceOn |
13 | Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504. DOI ScienceOn |
14 | Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-463. DOI ScienceOn |
15 | Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559. DOI ScienceOn |
16 | Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 2008;70(14 Pt 2):2364-2370. DOI |
17 | Song JX, Ren JY, Chen H. Primary and secondary hypocholesterolemia. Beijing Da Xue Xue Bao 2010;42:612-615. |
18 | Moutzouri E, Elisaf M, Liberopoulos EN. Hypocholesterolemia. Curr Vasc Pharmacol 2011;9:200-212. DOI ScienceOn |
19 | Levesque H, Gancel A, Pertuet S, Czernichow P, Courtois H. Hypocholesterolemia: prevalence, diagnostic and prognostic value: study in a department of internal medicine. Presse Med 1991;20:1935-1938. |
20 | American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35 Suppl 1:S64-S71. DOI |
21 | Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996;27:1993-1998. DOI ScienceOn |
22 | Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832. DOI ScienceOn |
23 | Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet 2001;357:922-925. DOI ScienceOn |
24 | Segal AZ, Chiu RI, Eggleston-Sexton PM, Beiser A, Greenberg SM. Low cholesterol as a risk factor for primary intracerebral hemorrhage: a case-control study. Neuroepidemiology 1999;18:185-193. DOI ScienceOn |
25 | Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011;103:508-519. DOI ScienceOn |
26 | Elmehdawi R. Hypolipidemia: a word of caution. Libyan J Med 2008;3:84-90. DOI |
27 | Vyroubal P, Chiarla C, Giovannini I, et al. Hypocholesterolemia in clinically serious conditions: review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:181-189. DOI ScienceOn |
28 | Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310. DOI ScienceOn |
29 | Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004;35:1360-1364. DOI ScienceOn |
30 | Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22. DOI ScienceOn |
31 | White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-326. DOI ScienceOn |
32 | Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001;103:387-392. DOI ScienceOn |
33 | Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248. DOI ScienceOn |
![]() |